Another clinical trial, for advanced ovarian tumors and recurrent ovarian cancer is investigating a combination of an anti-PDL1 antibody MEDI4736 with Olaparib and/or Cedinarib (NCT024844004). This evidence concerns the gene CD274 and ovarian carcinoma.